No takes yet. Share an insight, caveat, or question.
Randomized trial shows interferon-α increases megakaryocyte-biased stem cells in myeloproliferative neoplasms, indicating potential treatment benefits.
Rao et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: